Precirix Email Format
Biotechnology ResearchBrussels, Belgium11-50 Employees
Precirix is a clinical-stage biotechnology company focused on oncology, developing targeted radiopharmaceuticals that leverage camelid single-domain antibody fragments. Its lead candidate CAM-H2 is being evaluated in a Phase I/II trial for HER2-positive tumors, applying a theranostic approach that uses the same molecule for both imaging-based patient selection and therapy. The company is pursuing an expanding oncology pipeline beyond CAM-H2. It is based in Brussels, Belgium, operating as a small-to-mid-sized organization within the biotechnology research sector. In 2024, Precirix launched CAM-FAP-Ga-68 Academic Access Program to broaden access to its radiopharmaceuticals for research and academic settings. The company engages in partnerships and collaborations to advance its radiopharmaceutical platform and broaden access to relevant radioisotopes and compounds.